Skip to main content
Daito Pharmaceutical Co., Ltd. logo

Daito Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 4577 ISIN · JP3486150000 T Manufacturing
Open in API
Filings indexed 76 across all filing types
Latest filing 2023-10-13 Report Publication Anno…
Country JP Japan
Listing T 4577

About Daito Pharmaceutical Co., Ltd.

https://www.eng.daitonet.co.jp/

Daito Pharmaceutical Co., Ltd. is a manufacturer specializing in the integrated production of pharmaceuticals, from active pharmaceutical ingredients (APIs) to finished formulation products. The company's core activities include the development and supply of APIs, primarily for generic drugs, and the manufacturing of generic and over-the-counter (OTC) medications. Additionally, Daito provides contract manufacturing services for various pharmaceutical products. The company emphasizes a comprehensive quality assurance system to ensure the stable supply of high-quality products to its clients.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-4-8, Paragraph 1, in Japan. This specific document accompanies a Quarterly Report (Dai-ichi shihanki hokokusho) to confirm the accuracy of the financial statements. Since it is a formal regulatory filing required by the Japanese Financial Services Agency to accompany the quarterly report, and it does not contain the full financial report itself but rather the legal confirmation of its contents, it falls under the category of Regulatory Filings.
2023-10-13 Japanese
四半期報告書－第82期第1四半期(2023/06/01－2023/08/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement for the first quarter of the 82nd fiscal period (June 1, 2023, to August 31, 2023). It also includes management analysis, notes to financial statements, and audit review information. This fits the definition of an Interim/Quarterly Report (IR). Q1 2024
2023-10-13 Japanese
臨時報告書
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Rinji Hokokusho' (Extraordinary Report) filed with the Kanto Local Finance Bureau in Japan. It explicitly details the results of the 81st Annual General Meeting of Shareholders, including the specific voting counts (for/against/abstain) for the election of directors and audit committee members. According to the filing definitions, documents reporting the official results of shareholder votes at a general meeting are classified as 'Declaration of Voting Results & Voting Rights Announcements'.
2023-08-31 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan, specifically related to the accuracy of the Annual Securities Report (Yuuka Shouken Houkokusho). While it references the Annual Securities Report, it is a standalone regulatory filing confirming the validity of the report's contents. Since it does not fit into the specific categories for financial reports or announcements, it is classified as a Regulatory Filing (RNS). FY 2023
2023-08-30 Japanese
内部統制報告書－第81期(2022/06/01－2023/05/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法) in Japan. This type of report is a mandatory regulatory filing that assesses the effectiveness of a company's internal controls over financial reporting. Since it is a specific regulatory requirement distinct from a full Annual Report (10-K) or an Audit Report (AR), and it does not fit into the other specific categories provided, it is best classified as a Regulatory Filing (RNS).
2023-08-30 Japanese
有価証券報告書－第81期(2022/06/01－2023/05/31)
Annual Report Classification · 100% confidence The document is identified as a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the standard cover page details for such a filing, including the fiscal year (第81期), the submission date, and the regulatory body (Kanto Local Finance Bureau). The document structure and metadata confirm it is the comprehensive annual financial report for Daito Pharmaceutical Co., Ltd. FY 2023
2023-08-30 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.